As the number of COVID-19 cases increases in Europe, Minakem is putting its pharmaceutical production lines at the service of healthcare professionals to reduce the spread of coronavirus.
Dunkirk, March 25, 2020 – In order to meet the increased need for health services in France and Belgium in the face of the health crisis linked to COVID-19, Minakem, the subsidiary of the Minafin Group announces the provision of 1,600 medical masks and the production of 24 tons of hydroalcoholic gel in a pharmaceutical-grade environment. The gel and masks will be donated to hospitals free of charge, to the attention of the caregivers who are fighting this virus every day.
“As a major player in the production of active pharmaceutical ingredients for healthcare, we felt a responsibility to respond to the invitation of the French government and to contribute to the fight against the spread of the COVID-19 virus. We are currently planning to produce 24 tons of gel for healthcare facilities starting this week,” said Frédéric Gauchet, President of the Minafin Group. “The masks have already been delivered to the mayor of Dunkirk for distribution to healthcare professionals.”
In the face of this pandemic, all Minakem teams are mobilized to ensure the continuity of the deliveries of active ingredients to the pharmaceutical industry and to enable the industry to produce the medicines on which patients depend on.
Minakem specializes in the development of processes of active pharmaceutical ingredients and their industrial production. Minakem operates three European industrial sites in Dunkirk, Beuvry-la-Forêt, France, and Louvain-la-Neuve, Belgium approved by health authorities.
Focused on innovation, Minakem has two research and development centers with specialized services, led by a strong team of multidisciplinary scientists accompanying the pharmaceutical industry in the development of new synthesis pathways or in the transition from the laboratory phase to the industrial scale.
Thanks to its 530 employees and their know-how, Minakem contributes to the acceleration of the development cycles of new medicines. The company has a wide range of key technologies and pharmaceutical services aimed at increasing the competitiveness and sustainable growth of the pharmaceutical industry. Founded in 2004, Minakem is a subsidiary of the Minafin Group.
Media and analyst contacts
Andrew Lloyd & Associates
Carol Leslie – Juliette dos Santos
firstname.lastname@example.org – email@example.com
Tel: +44 1273 675 100
US: + 1 617 202 4491